Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prognostic Factors in FCR-Treated CLL
NCT00759798Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2008
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission at 6 months. Started Aug 2008; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00759798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759798.